Stock 603983 GUANGDONG MARUBI BIOTECHNOLOGY CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Guangdong Marubi Biotechnology Co., Ltd.

Equities

603983

CNE100003M51

End-of-day quote Shanghai S.E.
Other stock markets
 23:00:00 29/04/2024 BST 		5-day change 1st Jan Change
30.33 CNY +1.51% Intraday chart for Guangdong Marubi Biotechnology Co., Ltd. +7.86% +20.02%
04-26 Guangdong Marubi Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
2023 Guangdong Marubi Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • The company's profit outlook over the next few years is a strong asset.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • The opinion of analysts covering the stock has improved over the past four months.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

  • With an expected P/E ratio at 42.33 and 32.37 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The company's enterprise value to sales, at 4.79 times its current sales, is high.
  • The company appears highly valued given the size of its balance sheet.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Personal Products

1st Jan change Capi. Investor Rating ESG Refinitiv
GUANGDONG MARUBI BIOTECHNOLOGY CO., LTD. Stock Guangdong Marubi Biotechnology Co., Ltd.
+20.02% 1.68B
C+
L'ORÉAL Stock L'Oréal
-3.10% 251B
B-
KAO CORPORATION Stock Kao Corporation
+12.81% 19.44B
B+
GALDERMA GROUP AG Stock Galderma Group AG
0.00% 17.73B - -
SHISEIDO COMPANY, LIMITED Stock Shiseido Company, Limited
+0.38% 11.04B
A-
COTY INC. Stock Coty Inc.
-6.84% 10.11B
A-
AMOREPACIFIC CORPORATION Stock Amorepacific Corporation
+16.90% 7.51B
B+
PROYA COSMETICS CO.,LTD. Stock Proya Cosmetics Co.,Ltd.
+10.15% 5.97B
B
NATURA &CO HOLDING S.A. Stock Natura &Co Holding S.A.
-1.01% 4.42B
B+
INTER PARFUMS, INC. Stock Inter Parfums, Inc.
-17.67% 3.7B
C-
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 603983 Stock
  4. Ratings Guangdong Marubi Biotechnology Co., Ltd.